Spinning molecular immunology into successful immunotherapy - PubMed (original) (raw)
Review
doi: 10.1038/nri774.
Affiliations
- PMID: 12001994
- DOI: 10.1038/nri774
Review
Spinning molecular immunology into successful immunotherapy
Drew M Pardoll. Nat Rev Immunol. 2002 Apr.
Abstract
Until recently, immunotherapies have been of limited success, particularly against cancer. However, recent insights into the cells, molecules and signalling pathways that regulate immune responsiveness are providing new approaches for immunotherapy. In this article, I review some of the most promising molecular and cellular targets for immunotherapy and discuss approaches that use these targets to amplify immune responses and potentially break antigen-specific tolerance. These strategies provide a blueprint for the development of successful immunotherapy over the next decade.
Similar articles
- Poxviruses as vectors for cancer immunotherapy.
Kwak H, Hörig H, Kaufman HL. Kwak H, et al. Curr Opin Drug Discov Devel. 2003 Mar;6(2):161-8. Curr Opin Drug Discov Devel. 2003. PMID: 12669450 Review. - [Immunotherapy for cancer--modern immunologic strategies in oncology].
Halama N, Zoernig I, Jäger D. Halama N, et al. Dtsch Med Wochenschr. 2008 Oct;133(41):2105-8. doi: 10.1055/s-0028-1091251. Epub 2008 Oct 1. Dtsch Med Wochenschr. 2008. PMID: 18985564 Review. German. - Imaging the immune response to monitor tumor immunotherapy.
Wang Q, Ornstein M, Kaufman HL. Wang Q, et al. Expert Rev Vaccines. 2009 Oct;8(10):1427-37. doi: 10.1586/erv.09.100. Expert Rev Vaccines. 2009. PMID: 19803763 Review. - Viral vectors for gene transfer into antigen presenting cells.
Monahan SJ, Salgaller ML. Monahan SJ, et al. Curr Opin Mol Ther. 1999 Oct;1(5):558-64. Curr Opin Mol Ther. 1999. PMID: 11249662 Review. - Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells.
Breckpot K, Heirman C, Neyns B, Thielemans K. Breckpot K, et al. J Gene Med. 2004 Nov;6(11):1175-88. doi: 10.1002/jgm.615. J Gene Med. 2004. PMID: 15468193 Review.
Cited by
- Corosolic Acid Inhibits Secretory Phospholipase A2IIa as an Anti-Inflammatory Function and Exhibits Anti-Tumor Activity in Ehrlich Ascites Carcinoma Bearing Mice.
Pundalik S, Hanumappa KR, Giresha AS, Urs D, Rajashekarappa S, Muniyappa N, Jamballi G M, Kuaramkote Shivanna D, S Meti R, Anekere Dasappa Setty S, Thippegowda PB, Krishnappa DK. Pundalik S, et al. J Inflamm Res. 2022 Dec 31;15:6905-6921. doi: 10.2147/JIR.S383441. eCollection 2022. J Inflamm Res. 2022. PMID: 36619941 Free PMC article. - Advances in Nanotechnology for Cancer Immunoprevention and Immunotherapy: A Review.
Koyande NP, Srivastava R, Padmakumar A, Rengan AK. Koyande NP, et al. Vaccines (Basel). 2022 Oct 16;10(10):1727. doi: 10.3390/vaccines10101727. Vaccines (Basel). 2022. PMID: 36298592 Free PMC article. Review. - Efficacy of bivalent _CEACAM6/4-_1BBL genetic vaccine combined with anti-PD1 antibody in MC38 tumor model of mice.
Li Y, Zhu X, You J, Zhang B, Huang X, Jin C. Li Y, et al. Heliyon. 2022 Sep 28;8(10):e10775. doi: 10.1016/j.heliyon.2022.e10775. eCollection 2022 Oct. Heliyon. 2022. PMID: 36212004 Free PMC article. - Nanomedicines in B cell-targeting therapies.
Wang J, Yang J, Kopeček J. Wang J, et al. Acta Biomater. 2022 Jan 1;137:1-19. doi: 10.1016/j.actbio.2021.10.024. Epub 2021 Oct 21. Acta Biomater. 2022. PMID: 34687954 Free PMC article. Review. - Effect of Programmed Death-Ligand 1 in Cancer-Associated Fibroblasts on Advanced Laryngeal Squamous Cell Carcinoma.
Yang Z, Wang J, Chen C, Sun P, Yu Y. Yang Z, et al. Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211046432. doi: 10.1177/15330338211046432. Technol Cancer Res Treat. 2021. PMID: 34632870 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources